Cover Image
Market Research Report

Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles

Published by GBI Research Product code 245744
Published Content info 194 Pages
Immediate Delivery Available
Price
Back to Top
Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
Published: June 25, 2012 Content info: 194 Pages
Description

Summary

GBI Research in its report "Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles" presents the use of endpoints or outcomes measures in respiratory disease's clinical trials. In this report, endpoint used in asthma, cystic fibrosis, chronic obstructive pulmonary disorder and pulmonary arterial hypertension are presented. In this report detailed analysis about the clinical and surrogate endpoint used in various phases and stages of clinical trials are presented. This report presents detailed overview about the endpoint used in major marketed drugs and most promising molecules under development. The report contains company profiles of major companies involved with marketing of major marketed drugs under respiratory drug franchise.

Scope

  • The report starts with an executive summary, providing insights about the prominent endpoint used in respiratory clinical trials.
  • This report deals with different types of endpoint used in respiratory clinical trials. It contains brief account of advantages, disadvantages and regulatory aspects of each type of endpoint.
  • This report provides in-depth analysis of clinical trial endpoints used in asthma, COPD, cystic fibrosis and PAH clinical trials.
  • This report covers complete account of primary and secondary endpoints used in Phase III and Phase II clinical trials in above mentioned respiratory diseases.
  • In this report characterization and segmentation of trials based on their status, along with specific use of endpoints is also provided.
  • This report provides profiling of major marketed drugs based on their safety, efficacy and clinical study details.
  • The report contains company profiling of major companies associated with marketing of major respiratory drugs covering asthma, COPD, cystic fibrosis and PAH.
  • This report also includes endpoint analysis of terminated trials for asthma, COPD, cystic fibrosis and PAH. Analysis of terminated trials can be used in designing more robust trials and avoid any issues, which can result in termination of trial.

Reasons to buy

  • Understand the pattern of use of primary and secondary endpoints, according to specific indication's and clinical Phase of trial. This will help in designing clinical trials so as to and protect one's product from confronting any of the safety issues.
  • To analyze the major primary and secondary endpoint used in disease specific clinical trials.
  • Reinforce R&D strategies by identifying new endpoints to be used in disease and clinical phase specific clinical trials. This can increase positive outcome from a trial and aid in bringing molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus of major companies developing drugs in respiratory franchise.
  • Build effective strategies by clinical phase wise endpoint analysis of clinical trials. This can help in reducing the drug's time to market.
  • Exploit strategies for designing of clinical trials by identifying the advantages and disadvantages involved with the use of specific endpoints.

Executive Summary

Standardized Clinical Trials Endpoints to Help Health Authorities Tackle Respiratory Diseases.

We all know that smoking and some allergies are bad for our lungs, but now science is standardizing the way that we measure respiratory health, helping to judge the effectiveness of drug treatments better than ever, according to a new report by healthcare experts GBI Research.

The new report* shows that asthma and chronic obstructive pulmonary disorder (COPD), common conditions causing breathing difficulties, are now being studied using a set of common clinical endpoints, which help to standardize test results and draw conclusions regarding the effectiveness of new drugs.

COPD is cited as the fourth most common cause of death in the US by the National Institute of Health, representing a collection of progressive lung diseases including emphysema and chronic bronchitis, often caused by smoking, and is proving a heavy economic burden for state healthcare. Therefore, is has been imperative for health authorities to further improve on their endpoint measurements in order to compare the available treatment options for these disorders.

Clinical trial endpoints are used to measure the outcomes of medical testing, assessing the effects of new treatments. Endpoints in respiratory disease clinical trials should be accurate, precise, easily measurable and reliable, and range from techniques such as daily symptoms scoring, use of rescue medication and the quality of life score, to more specific vital signs such as measuring pulmonary function, respiratory rate and pulse.

The endpoints used in respiratory clinical trials are often chosen depending on the developmental stage of the molecule being studied, as agencies require Phase III trials to study direct clinical endpoints in order to grant drug approvals.

Physicians confirm diagnoses of asthma using pulmonary function tests (PFT), and classify the condition based on Peak Expiratory Flow (PEF) rate, frequency of symptoms and Forced Expiratory Volume (FEV). It is therefore not surprising that FEV was used in 29.9% of completed Phase III clinical trials for asthma products as a primary endpoint during 2000-2010, while another 29.3% of these trials used multiple PFT as a secondary endpoint.

Similarly, 49.2% of phase III COPD clinical trials during 2000-010 used FEV as a primary endpoint, while 20.3% used multiple PFTs as endpoints. PFTs were employed as a primary endpoint in 64 completed clinical trials for asthma and COPD.

Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles

This report presents the use of endpoints or outcome measures in respiratory disease's clinical trials for asthma, cystic fibrosis, chronic obstructive pulmonary disorder and pulmonary arterial hypertension. Detailed analysis about the clinical and surrogate endpoint used in various phases and stages of clinical trials are presented. This report presents detailed overview about the endpoint used in major marketed drugs and most promising molecules under development. It also contains company profiles of major companies involved with marketing of major marketed drugs under respiratory drug franchise.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

3. Clinical Trials Endpoints in Respiratory Diseases - An Overview

  • 3.1. Introduction
  • 3.2. Types of Endpoints
    • 3.2.1. Primary Endpoints
    • 3.2.2. Secondary Endpoints
    • 3.2.3. Surrogate Endpoints

4. Endpoints - Clinical Trials in Asthma - Marketed and Pipeline Products Assessment

  • 4.1. Introduction
  • 4.2. Primary Endpoints Used in Asthma Clinical Trials
    • 4.2.1. Pulmonary Function Tests:
    • 4.2.2. Vital Signs and Physical Activity
    • 4.2.3. Biomarkers
    • 4.2.4. Serious Adverse Events
  • 4.3. Secondary Endpoints Used in Asthma Clinical Trials
    • 4.3.1. Pharmacokinetics and Pharmacodynamics
    • 4.3.2. Quality of Life Scores
    • 4.3.3. Clinical Laboratory Tests - Biochemistry and Serum Hematology
    • 4.3.4. Use of Rescue Medication
  • 4.4. Asthma Therapeutics - Major Marketed Drugs
    • 4.4.1. Singulair (Montekeulast Sodium)
    • 4.4.2. Accolate Accoleit, Vanticon (Zafirlukast)
    • 4.4.3. Zyflo (Zileuton)
    • 4.4.4. Foradil (Formoterol Fumarate Inhalation Powder)
    • 4.4.5. Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol)
    • 4.4.6. Xolair (Omalizumab)
    • 4.4.7. Serevent Diskus (Salmaterol Xinafoate Inhalation Powder)
    • 4.4.8. Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder)
  • 4.5. Asthma Therapeutics - Promising Drugs under Clinical Development
    • 4.5.1. Daxas (Roflumilast) (Daxas, APTA 2217, B9302-107, BY 217, BYK 20869)
  • 4.6. Phase III Clinical Trial Analysis
    • 4.6.1. Completed Trial Analysis
    • 4.6.2. Active Trial Analysis
    • 4.6.3. Terminated Trial Analysis
  • 4.7. Phase II Clinical Trial Analysis
    • 4.7.1. Completed Trial Analysis
    • 4.7.2. Active Trial Analysis
    • 4.7.3. Terminated Trial Analysis

5. Endpoints - Clinical Trials in Chronic Obstructive Pulmonary Disorder - Marketed and Pipeline Products Assessment

  • 5.1. Introduction
  • 5.2. Primary Endpoints Used in COPD Clinical Trials
    • 5.2.1. Pulmonary Function Tests
    • 5.2.2. Baseline Dyspnea Index and Borg-Dyspnea Score
    • 5.2.3. Rate of Exacerbations
    • 5.2.4. Induced Sputum Analysis
    • 5.2.5. Biomarkers of COPD
  • 5.3. Secondary Endpoints Used in COPD Clinical Trials
    • 5.3.1. Exercise Endurance Time
    • 5.3.2. Serum Hematology
    • 5.3.3. Six Minute Walk Distance
    • 5.3.4. Time to First Exacerbation
  • 5.4. COPD Therapeutics - Major Marketed Drugs
    • 5.4.1. Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder)
    • 5.4.2. Brovana (Arformoterol)
    • 5.4.3. Foradil Aerolizer (Formoterol Fumarate Inhalation Powder)
    • 5.4.4. Symbicort (Budesonide/Formoterol Fumarate Dihydrate)
    • 5.4.5. Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder)
    • 5.4.6. Daxas (roflumilast)
  • 5.5. COPD Therapeutics - Promising Drugs Under Clinical Development
    • 5.5.1. Aclidinium Bromide
    • 5.5.2. NVA237(Glycopyrronium Bromide)
    • 5.5.3. Dulera
  • 5.6. Phase III Clinical Trial Analysis
    • 5.6.1. Completed Trial Analysis
    • 5.6.2. Active Trials Analysis
    • 5.6.3. Terminated Trial Analysis
  • 5.7. Phase II Clinical Trial Analysis
    • 5.7.1. Completed Trial Analysis
    • 5.7.2. Active Trial Analysis
    • 5.7.3. Terminated Trial Analysis

6. Endpoints - Clinical Trials in Cystic Fibrosis - Marketed and Pipeline Products Assessment

  • 6.1. Introduction
  • 6.2. Primary Endpoints Used in Cystic Fibrosis Clinical Trials
    • 6.2.1. Coefficient of Fat Absorption
    • 6.2.2. Lung Microbiology
    • 6.2.3. Biomarkers
  • 6.3. Secondary Endpoints Used in Cystic Fibrosis Clinical Trials
    • 6.3.1. Nasal Potential Difference
    • 6.3.2. Sweat Chloride Concentration
  • 6.4. Cystic Fibrosis Therapeutics - Major Marketed Drugs
    • 6.4.1. Tobi (Tobramycin Inhalation Solution)
    • 6.4.2. Pulmozyme (Dornase Alfa)
    • 6.4.3. Cayston (aztreonam for Inhalation Solution)
    • 6.4.4. Colistimethate sodium (Colistin, Colomycin Injection, Promixin, Coly-Mycin M)
  • 6.5. Cystic Fibrosis - Promising Drugs Under Clinical Development
    • 6.5.1. Denufosol Tetrasodium Inhalation Solution (INS37217)
    • 6.5.2. VX-770
    • 6.5.3. Bronchitol
    • 6.5.4. Ataluren (PTC-124)
  • 6.6. Phase III - Clinical Trial Analysis
    • 6.6.1. Completed Trial Analysis
    • 6.6.2. Active Trial Analysis
    • 6.6.3. Terminated Trial Analysis
  • 6.7. Phase II - Clinical Trial Analysis
    • 6.7.1. Completed Trial Analysis
    • 6.7.2. Active Trial Analysis
    • 6.7.3. Terminated Trial Analysis

7. Endpoints - Clinical Trials in Pulmonary Arterial Hypertension - Marketed and Pipeline Products Assessment

  • 7.1. Introduction
    • 7.1.1. Classification of Pulmonary Hypertension
  • 7.2. Primary Endpoints Used in Pulmonary Hypertension Trials
    • 7.2.1. Cardiopulmonary Hemodynamic Test
    • 7.2.2. Six Minutes Walking Distance
    • 7.2.3. Biomarkers
  • 7.3. Secondary Endpoints Used in Pulmonary Hypertension Trials
    • 7.3.1. Time to Clinical Worsening
    • 7.3.2. SF-36 Health Survey
  • 7.4. Pulmonary Arterial Hypertension - Major Marketed Drugs
    • 7.4.1. Tracleer
    • 7.4.2. Remodulin
    • 7.4.3. Revatio
    • 7.4.4. Ventavis
    • 7.4.5. Letairis
    • 7.4.6. Adcirca
  • 7.5. Pulmonary Arterial Hypertension - Promising Drugs under Clinical Development
    • 7.5.1. ACT-064992
    • 7.5.2. Oral Treprostinil
    • 7.5.3. ACT-293987
    • 7.5.4. Riociguat (BAY63-2521)
  • 7.6. Phase III Clinical Trial Analysis
    • 7.6.1. Completed Trial Analysis
    • 7.6.2. Active Trial Analysis
    • 7.6.3. Terminated Trial Analysis
  • 7.7. Phase II Clinical Trial Analysis
    • 7.7.1. Completed Trial Analysis
    • 7.7.2. Active Trial Analysis
    • 7.7.3. Terminated Trial Analysis

8. Endpoints - Clinical Trials in Respiratory Diseases - Company Profiling

  • 8.1. GlaxoSmithKline Plc
    • 8.1.1. Overview
    • 8.1.2. Respiratory Disease Portfolio
  • 8.2. AstraZeneca
    • 8.2.1. Overview
    • 8.2.2. Respiratory Disease Portfolio
  • 8.3. F.Hoffmann La Roche
    • 8.3.1. Overview
    • 8.3.2. Respiratory Disease Portfolio
  • 8.4. Merck & Co Inc
    • 8.4.1. Overview
    • 8.4.2. Respiratory Disease Portfolio
  • 8.5. Novartis AG
    • 8.5.1. Overview
    • 8.5.2. Respiratory Disease Portfolio
  • 8.6. Boehringer Ingelheim GmbH
    • 8.6.1. Overview
    • 8.6.2. Respiratory Disease Portfolio

9. Clinical Trials Endpoints in Respiratory Therapeutics - Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Sources
  • 9.4. Research Methodology
    • 9.4.1. Clinical Trial Design Overview
    • 9.4.2. Top Four Indications in Respiratory Therapy Area and their Product Profiling
    • 9.4.3. Marketed and Pipeline Products Assessment
    • 9.4.4. Company Profiling
    • 9.4.5. Expert Panel Validation
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Distribution of Clinical Trials, By Company, 2000-2010
  • Table 2: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010
  • Table 3: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010
  • Table 4: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010
  • Table 5: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010
  • Table 6: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010
  • Table 7: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010
  • Table 8: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010
  • Table 9: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010
  • Table 10: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010
  • Table 11: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010
  • Table 12: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010
  • Table 13: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010
  • Table 14: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Phase III Clinical Trials, 2000-2010
  • Table 15: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Phase II Clinical Trials, 2000-2010
  • Table 16: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Distribution of Clinical Trials, By Company, 2000-2010
  • Table 17: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010
  • Table 18: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010
  • Table 19: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010
  • Table 20: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010
  • Table 21: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010
  • Table 22: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010
  • Table 23: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010
  • Table 24: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010
  • Table 25: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010
  • Table 26: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010
  • Table 27: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010
  • Table 28: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010
  • Table 29: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Phase III Clinical Trials, 2000-2010
  • Table 30: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Phase II Clinical Trials, 2000-2010
  • Table 31: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Distribution of Clinical Trials, By Company, 2000-2010
  • Table 32: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010
  • Table 33: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010
  • Table 34: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010
  • Table 35: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010
  • Table 36: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010
  • Table 37: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010
  • Table 38: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010
  • Table 39: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010
  • Table 40: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010
  • Table 41: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010
  • Table 42: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010
  • Table 43: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010
  • Table 44: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Phase III Clinical Trials, 2000-2010
  • Table 45: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Phase II Clinical Trials, 2000-2010
  • Table 46: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Distribution of Clinical Trials, By Company, 2002-2010
  • Table 47: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2002-2010
  • Table 48: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2002-2010
  • Table 49: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2002-2010
  • Table 50: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2002-2010
  • Table 51: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2002-2010
  • Table 52: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2002-2010
  • Table 53: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2002-2010
  • Table 54: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2002-2010
  • Table 55: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2002-2010
  • Table 56: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2002-2010
  • Table 57: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2002-2010
  • Table 58: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2002-2010
  • Table 59: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Phase III Clinical Trials, 2002-2010
  • Table 60: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Phase II Clinical Trials, 2002-2010
  • Table 61: GlaxoSmithKline Plc, Marketed Respiratory Drugs Portfolio, 2010
  • Table 62: AstraZeneca, Marketed Respiratory Drugs Portfolio, 2010
  • Table 63: F.Hoffmann La Roche, Marketed Respiratory Drugs Portfolio, 2010
  • Table 64: Merck & Co, Marketed Respiratory Drugs Portfolio, 2010
  • Table 65: Novartis AG, Marketed Respiratory Drugs Portfolio, 2010
  • Table 66: Boehringer Ingelheim, Marketed Respiratory Drugs Portfolio, 2010

List of Figures

  • Figure 1: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Total Number Of Clinical Trials, 2000-2010
  • Figure 2: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Phase of Clinical Trials, 2000-2010
  • Figure 3: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Status of Clinical Trials, 2000-2010
  • Figure 4: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Distribution of Clinical Trials, By Company (%), 2000-2010
  • Figure 5: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010
  • Figure 6: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010
  • Figure 7: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010
  • Figure 8: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010
  • Figure 9: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010
  • Figure 10: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010
  • Figure 11: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010
  • Figure 12: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010
  • Figure 13: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010
  • Figure 14: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010
  • Figure 15: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010
  • Figure 16: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010
  • Figure 17: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Total Number of Clinical Trials, 2000-2010
  • Figure 18: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Phase of Clinical Trials, 2000-2010
  • Figure 19: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Status of Clinical Trials, 2000-2010
  • Figure 20: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Distribution of Clinical Trials, By Company (%), 2000-2010
  • Figure 21: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010
  • Figure 22: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010
  • Figure 23: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010
  • Figure 24: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010
  • Figure 25: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010
  • Figure 26: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010
  • Figure 27: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010
  • Figure 28: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010
  • Figure 29: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010
  • Figure 30: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010
  • Figure 31: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010
  • Figure 32: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010
  • Figure 33: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Total Number of Clinical Trials, 2000-2010
  • Figure 34: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Phase of Clinical Trials, 2000-2010
  • Figure 35: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Status of Clinical Trials, 2000-2010
  • Figure 36: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Distribution of Clinical Trials, By Company (%), 2000-2010
  • Figure 37: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010
  • Figure 38: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010
  • Figure 39: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010
  • Figure 40: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010
  • Figure 41: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010
  • Figure 42: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010
  • Figure 43: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010
  • Figure 44: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010
  • Figure 45: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010
  • Figure 46: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010
  • Figure 47: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010
  • Figure 48: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010
  • Figure 49: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Total Number of Clinical Trials, 2002-2010
  • Figure 50: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Phase of Clinical Trials, 2002-2010
  • Figure 51: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Status of Clinical Trials, 2002-2010
  • Figure 52: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Distribution of Clinical Trials, By Company (%),2002-2010
  • Figure 53: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2002-2010
  • Figure 54: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2002-2010
  • Figure 55: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2002-2010
  • Figure 56: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2002-2010
  • Figure 57: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2002-2010
  • Figure 58: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%),2002-2010
  • Figure 59: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2002-2010
  • Figure 60: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2002-2010
  • Figure 61: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2002-2010
  • Figure 62: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2002-2010
  • Figure 63: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2002-2010
  • Figure 64: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2002-2010
Back to Top